Bristol Myers SquibbBMYEarnings & Financial Report
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...
BMY Q4 2025 Key Financial Metrics
营收
$12.5B
毛利润
$8.4B
营业利润
N/A
净利润
$1.1B
毛利率
67.2%
营业利润率
N/A
净利率
8.7%
同比增长
1.3%
EPS
$0.54
资金流向
Bristol Myers Squibb Q4 2025 Financial Summary
Bristol Myers Squibb reported revenue of $12.5B for Q4 2025, with a net profit of $1.1B (8.7% margin). Cost of goods sold was $4.1B, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $12.5B |
|---|---|
| Net Profit | $1.1B |
| Gross Margin | 67.2% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Bristol Myers Squibb Annual Revenue by Year
Bristol Myers Squibb annual revenue history includes year-by-year totals (for example, 2025 revenue was $48.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $48.2B |
| 2024 | $48.3B |
| 2023 | $45.0B |
| 2022 | $46.2B |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $11.87B | $12.20B | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B |
| 同比增长 | 4.7% | 8.7% | 8.4% | 7.5% | -5.6% | 0.6% | 2.8% | 1.3% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $99.03B | $94.65B | $93.67B | $92.60B | $92.43B | $94.68B | $96.89B | $90.04B |
| 总负债 | $82.48B | $77.58B | $76.47B | $76.22B | $74.98B | $77.19B | $78.29B | $71.53B |
| 股东权益 | $16.49B | $17.02B | $17.14B | $16.34B | $17.39B | $17.43B | $18.55B | $18.47B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $2.83B | $2.33B | $5.59B | $4.44B | $1.95B | $3.92B | $6.31B | $1.97B |
Other Health Care Companies
JNJ
Johnson & Johnson
营收
$24.6B
净利润
$5.1B
LLY
Lilly (Eli)
营收
$19.3B
净利润
$6.6B
MRK
Merck & Co.
营收
$17.3B
净利润
$5.8B
PFE
Pfizer
营收
$16.7B
净利润
$3.5B
VTRS
Viatris
营收
$3.7B
净利润
N/A
ZTS
Zoetis
营收
$2.4B
净利润
$603.0M
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
ABBV
AbbVie
营收
$15.8B
净利润
$186.0M
A
Agilent Technologies
营收
$1.9B
净利润
$434.0M
ALGN
Align Technology
营收
$995.7M
净利润
$56.8M